Literature DB >> 24390716

N-Acetylcysteine and metabotropic glutamate receptors: implications for the treatment of schizophrenia: a literature review.

Adam Daniel Zavodnick1, Rizwan Ali.   

Abstract

The objective of this study is to review the available data regarding metabotropic glutamate receptors in the pathology of Schizophrenia. Further, to investigate the potential utility of N-acetylcysteine as it relates to metabotropic glutamate receptors. A PubMed based literature review was conducted using keywords related to glutamate receptors, Schizophrenia and N-acetylcysteine from June 2012 through August of 2012. Relevant cited references of selected articles were also reviewed. The knowledge base regarding glutamate receptors, both ionotropic and metabotropic is rapidly expanding. New agonists of various subsets of metabotropic glutamate receptors are available and have demonstrated potential utility in animal models. N-acetylcysteine indirectly stimulates presynaptic metabotropic glutamate receptors and has shown efficacy in two double-blind randomized controlled trials. Metabotropic glutamate receptors contribute to an understanding of glutamate dysfunction in Schizophrenia. Agents which lead to stimulation of metabotropic glutamate receptors, inclusive of N-acetylcysteine show promise as novel agents in the treatment of this disorder. An understanding of the various metabotropic glutamate receptors will be a growing necessity as agents which target them continue to emerge and enter clinical trials.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24390716     DOI: 10.1007/s11126-013-9281-3

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  27 in total

Review 1.  From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.

Authors:  Bita Moghaddam; Daniel Javitt
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Ikwunga Wonodi; Rosalinda C Roberts; Arash Rassoulpour; Robert P McMahon; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2010-10-29       Impact factor: 9.306

3.  NMDA/AMPA ratio impacts state transitions and entrainment to oscillations in a computational model of the nucleus accumbens medium spiny projection neuron.

Authors:  John A Wolf; Jason T Moyer; Maciej T Lazarewicz; Diego Contreras; Marianne Benoit-Marand; Patricio O'Donnell; Leif H Finkel
Journal:  J Neurosci       Date:  2005-10-05       Impact factor: 6.167

4.  N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.

Authors:  Giancarlo Marenzi; Emilio Assanelli; Ivana Marana; Gianfranco Lauri; Jeness Campodonico; Marco Grazi; Monica De Metrio; Stefano Galli; Franco Fabbiocchi; Piero Montorsi; Fabrizio Veglia; Antonio L Bartorelli
Journal:  N Engl J Med       Date:  2006-06-29       Impact factor: 91.245

5.  Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking.

Authors:  Megan M Moran; Krista McFarland; Roberto I Melendez; Peter W Kalivas; Jeremy K Seamans
Journal:  J Neurosci       Date:  2005-07-06       Impact factor: 6.167

6.  Glutamatergic modulation of auditory information processing in the human brain.

Authors:  Handan Gunduz-Bruce; Robert M G Reinhart; Brian J Roach; Ralitza Gueorguieva; Stephen Oliver; Deepak C D'Souza; Judith M Ford; John H Krystal; Daniel H Mathalon
Journal:  Biol Psychiatry       Date:  2011-10-29       Impact factor: 13.382

7.  The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial.

Authors:  Michael Berk; Olivia Dean; Sue M Cotton; Clarissa S Gama; Flavio Kapczinski; Brisa S Fernandes; Kristy Kohlmann; Susan Jeavons; Karen Hewitt; Christine Allwang; Heidi Cobb; Ashley I Bush; Ian Schapkaitz; Seetal Dodd; Gin S Malhi
Journal:  J Affect Disord       Date:  2011-06-29       Impact factor: 4.839

Review 8.  N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.

Authors:  Olivia Dean; Frank Giorlando; Michael Berk
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

9.  Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence.

Authors:  René Gysin; Rudolf Kraftsik; Julie Sandell; Pierre Bovet; Céline Chappuis; Philippe Conus; Patricia Deppen; Martin Preisig; Viviane Ruiz; Pascal Steullet; Mirjana Tosic; Thomas Werge; Michel Cuénod; Kim Q Do
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-05       Impact factor: 11.205

10.  Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine.

Authors:  Goro Fukami; Kenji Hashimoto; Kaori Koike; Naoe Okamura; Eiji Shimizu; Masaomi Iyo
Journal:  Brain Res       Date:  2004-07-30       Impact factor: 3.252

View more
  4 in total

1.  Targeting Glia with N-Acetylcysteine Modulates Brain Glutamate and Behaviors Relevant to Neurodevelopmental Disorders in C57BL/6J Mice.

Authors:  Alice M S Durieux; Cathy Fernandes; Declan Murphy; Marie Anais Labouesse; Sandra Giovanoli; Urs Meyer; Qi Li; Po-Wah So; Grainne McAlonan
Journal:  Front Behav Neurosci       Date:  2015-12-14       Impact factor: 3.558

2.  N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence.

Authors:  Soo Liang Ooi; Ruth Green; Sok Cheon Pak
Journal:  Biomed Res Int       Date:  2018-10-22       Impact factor: 3.411

Review 3.  Hippocampal Hyperactivity as a Druggable Circuit-Level Origin of Aberrant Salience in Schizophrenia.

Authors:  Dennis Kätzel; Amy R Wolff; Alexei M Bygrave; David M Bannerman
Journal:  Front Pharmacol       Date:  2020-10-16       Impact factor: 5.810

4.  Chronic N-acetylcysteine treatment improves anhedonia and cognition in a mouse model of the schizophrenia prodrome.

Authors:  Lukas Marius Bühner; Sampath K T Kapanaiah; Dennis Kätzel
Journal:  Front Behav Neurosci       Date:  2022-09-26       Impact factor: 3.617

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.